183 related articles for article (PubMed ID: 15618202)
1. Shiga-toxigenic Escherichia coli-inoculated neonatal piglets develop kidney lesions that are comparable to those in humans with hemolytic-uremic syndrome.
Pohlenz JF; Winter KR; Dean-Nystrom EA
Infect Immun; 2005 Jan; 73(1):612-6. PubMed ID: 15618202
[TBL] [Abstract][Full Text] [Related]
2. Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with enterohemorrhagic Escherichia coli.
Gunzer F; Hennig-Pauka I; Waldmann KH; Sandhoff R; Gröne HJ; Kreipe HH; Matussek A; Mengel M
Am J Clin Pathol; 2002 Sep; 118(3):364-75. PubMed ID: 12219778
[TBL] [Abstract][Full Text] [Related]
3. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections.
Watanabe M; Matsuoka K; Kita E; Igai K; Higashi N; Miyagawa A; Watanabe T; Yanoshita R; Samejima Y; Terunuma D; Natori Y; Nishikawa K
J Infect Dis; 2004 Feb; 189(3):360-8. PubMed ID: 14745692
[TBL] [Abstract][Full Text] [Related]
4. Contribution of polyunsaturated fatty acids to Shiga toxin cytotoxicity in human renal tubular epithelium-derived cells.
Sasaki TK; Takita T
Biochem Cell Biol; 2006 Apr; 84(2):157-66. PubMed ID: 16609696
[TBL] [Abstract][Full Text] [Related]
5. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury.
Müthing J; Schweppe CH; Karch H; Friedrich AW
Thromb Haemost; 2009 Feb; 101(2):252-64. PubMed ID: 19190807
[TBL] [Abstract][Full Text] [Related]
6. Conserved Stx2 phages from Escherichia coli O103:H25 isolated from patients suffering from hemolytic uremic syndrome.
Sekse C; Muniesa M; Wasteson Y
Foodborne Pathog Dis; 2008 Dec; 5(6):801-10. PubMed ID: 19014273
[TBL] [Abstract][Full Text] [Related]
7. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome.
Orth D; Grif K; Khan AB; Naim A; Dierich MP; Würzner R
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):235-42. PubMed ID: 17931818
[TBL] [Abstract][Full Text] [Related]
8. Shiga Toxin (Stx)-Binding Glycosphingolipids of Primary Human Renal Cortical Epithelial Cells (pHRCEpiCs) and Stx-Mediated Cytotoxicity.
Detzner J; Krojnewski E; Pohlentz G; Steil D; Humpf HU; Mellmann A; Karch H; Müthing J
Toxins (Basel); 2021 Feb; 13(2):. PubMed ID: 33673393
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome.
Brigotti M; Tazzari PL; Ravanelli E; Carnicelli D; Rocchi L; Arfilli V; Scavia G; Minelli F; Ricci F; Pagliaro P; Ferretti AV; Pecoraro C; Paglialonga F; Edefonti A; Procaccino MA; Tozzi AE; Caprioli A
Pediatr Infect Dis J; 2011 Jun; 30(6):486-90. PubMed ID: 21164386
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections.
Serna A; Boedeker EC
Curr Opin Gastroenterol; 2008 Jan; 24(1):38-47. PubMed ID: 18043231
[TBL] [Abstract][Full Text] [Related]
11. Subtyping method for Escherichia coli shiga toxin (verocytotoxin) 2 variants and correlations to clinical manifestations.
Persson S; Olsen KE; Ethelberg S; Scheutz F
J Clin Microbiol; 2007 Jun; 45(6):2020-4. PubMed ID: 17446326
[TBL] [Abstract][Full Text] [Related]
12. A case of hemolytic-uremic syndrome associated with shiga toxin 2-producing Escherichia coli O121 infection caused by drinking water contaminated with bovine feces.
Yatsuyanagi J; Saito S; Ito I
Jpn J Infect Dis; 2002 Oct; 55(5):174-6. PubMed ID: 12501259
[No Abstract] [Full Text] [Related]
13. New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome.
Karch H; Friedrich AW; Gerber A; Zimmerhackl LB; Schmidt MA; Bielaszewska M
Semin Thromb Hemost; 2006 Mar; 32(2):105-12. PubMed ID: 16575685
[TBL] [Abstract][Full Text] [Related]
14. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues.
Karmali MA
J Infect Dis; 2004 Feb; 189(3):355-9. PubMed ID: 14745691
[No Abstract] [Full Text] [Related]
15. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes.
Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA
Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697
[TBL] [Abstract][Full Text] [Related]
16. Relationship between susceptibility to hemolytic-uremic syndrome and levels of globotriaosylceramide in human sera.
Watarai S; Yokota K; Tana ; Kishimoto T; Kanadani T; Taketa K; Oguma K
J Clin Microbiol; 2001 Feb; 39(2):798-800. PubMed ID: 11158156
[TBL] [Abstract][Full Text] [Related]
17. "Children on the frontline against E. coli": typical hemolytic-uremic syndrome.
Andersen H
Clin Lab Sci; 2005; 18(2):90-9. PubMed ID: 15916241
[TBL] [Abstract][Full Text] [Related]
18. Identification of TLR4 as the receptor that recognizes Shiga toxins in human neutrophils.
Brigotti M; Carnicelli D; Arfilli V; Tamassia N; Borsetti F; Fabbri E; Tazzari PL; Ricci F; Pagliaro P; Spisni E; Cassatella MA
J Immunol; 2013 Nov; 191(9):4748-58. PubMed ID: 24068665
[TBL] [Abstract][Full Text] [Related]
19. A glucosylceramide synthase inhibitor protects rats against the cytotoxic effects of shiga toxin 2.
Silberstein C; Lucero MS; Zotta E; Copeland DP; Lingyun L; Repetto HA; Ibarra C
Pediatr Res; 2011 May; 69(5 Pt 1):390-4. PubMed ID: 21270676
[TBL] [Abstract][Full Text] [Related]
20. [New drugs that prevent cytotoxicity of Shiga toxins].
Natori Y
Nihon Rinsho; 2002 Jun; 60(6):1131-7. PubMed ID: 12078085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
